In the last five years, more psychotropics have gained approval through the FDA’s expedited pathways than the slow and cautious routes we’ve grown used to. These “fast-track” and “breakthrough therapy” approvals allow drugs to enter the market on the basis of more efficient (ie, smaller) clinical trials.

Most patients with bipolar disorder have cognitive complaints, but it’s a mistake to diagnose them all with ADHD, and a mistake to miss the genuine ADHD-bipolar comorbidity as well. Inside, a step-by-step guide to teasing apart the diagnoses.

Omega-3s are helpful for negative symptoms in schizophrenia, and this study suggests they may have metabolic benefits as well.

This new study is the first placebo-controlled trial to examine the long-term effects of an SSRI in bipolar disorder.

Lamotrigine is approved for the prevention of bipolar episodes, but Dr. Aiken explains why it may also treat active bipolar depression. This mood stabilizer is among the most tolerable in its class, and has additional benefits in OCD, borderline personality disorder, and depersonalization disorder.

After digging through 3 decades of research, we can tell you this: There is no such thing as “the best” SSRI. But there are some important differences between them, and this article will show you how to find the right one for your patient.

This German medication outperformed paroxetine in generalized anxiety disorder and is available over the counter in the U.S.

An atypical antipsychotic with a novel mechanism shows promise in bipolar depression.

Provigil and Nuvigil, the modafinils, may not work for full depressive episodes, but they do something else in bipolar disorder that’s important to patients. This article explores their cognitive effects, as well as their potential to cause addiction and mania.